Riverhead Capital Management’s IGM Biosciences IGMS Stock Holding History

Riverhead Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$110K	Buy	+6,206	New	+$125K	﹤0.01%	1309

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Riverhead Capital Management's IGMS Position: Q3 2019 in Review

Riverhead Capital Management opened a new position in IGM Biosciences (IGMS) in Q3 2019: 6,206 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #1309 among its holdings.

33 funds tracked by Wall St. Rank hold IGMS as of Q3 2019.

Riverhead Capital Management held 6,206 shares of IGM Biosciences worth $110K as of Q3 2019.
IGM Biosciences was a new Riverhead Capital Management position in Q3 2019.
IGM Biosciences made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1309 holding.
33 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.